CWEB vs. MDP, HEXO, VIR, ZOM, META, LABS, DB, VM, NRTH, and MRV
Should you be buying Charlotte's Web stock or one of its competitors? The main competitors of Charlotte's Web include Medexus Pharmaceuticals (MDP), HEXO (HEXO), Viridium Pacific Group (VIR), Zomedica Pharmaceuticals Corp. (ZOM.V) (ZOM), Meta Growth (META), MediPharm Labs (LABS), Decibel Cannabis (DB), Voyageur Pharmaceuticals (VM), 48North Cannabis (NRTH), and Nuvo Pharmaceuticals (MRV). These companies are all part of the "drug manufacturers - specialty & generic" industry.
Charlotte's Web vs.
Medexus Pharmaceuticals (TSE:MDP) and Charlotte's Web (TSE:CWEB) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, dividends, institutional ownership, earnings, valuation, media sentiment, profitability, community ranking and analyst recommendations.
Medexus Pharmaceuticals has a beta of 1.96, meaning that its stock price is 96% more volatile than the S&P 500. Comparatively, Charlotte's Web has a beta of 1.91, meaning that its stock price is 91% more volatile than the S&P 500.
Medexus Pharmaceuticals has a net margin of 3.25% compared to Charlotte's Web's net margin of -66.35%. Medexus Pharmaceuticals' return on equity of 11.07% beat Charlotte's Web's return on equity.
Medexus Pharmaceuticals received 10 more outperform votes than Charlotte's Web when rated by MarketBeat users. Likewise, 71.43% of users gave Medexus Pharmaceuticals an outperform vote while only 0.00% of users gave Charlotte's Web an outperform vote.
In the previous week, Medexus Pharmaceuticals had 1 more articles in the media than Charlotte's Web. MarketBeat recorded 1 mentions for Medexus Pharmaceuticals and 0 mentions for Charlotte's Web. Medexus Pharmaceuticals' average media sentiment score of 1.34 beat Charlotte's Web's score of 0.00 indicating that Medexus Pharmaceuticals is being referred to more favorably in the media.
Medexus Pharmaceuticals has higher revenue and earnings than Charlotte's Web. Charlotte's Web is trading at a lower price-to-earnings ratio than Medexus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
8.3% of Medexus Pharmaceuticals shares are owned by institutional investors. Comparatively, 3.3% of Charlotte's Web shares are owned by institutional investors. 9.1% of Medexus Pharmaceuticals shares are owned by insiders. Comparatively, 11.3% of Charlotte's Web shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Medexus Pharmaceuticals currently has a consensus target price of C$5.49, indicating a potential upside of 116.04%. Given Medexus Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Medexus Pharmaceuticals is more favorable than Charlotte's Web.
Summary
Medexus Pharmaceuticals beats Charlotte's Web on 18 of the 19 factors compared between the two stocks.
Get Charlotte's Web News Delivered to You Automatically
Sign up to receive the latest news and ratings for CWEB and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Charlotte's Web Competitors List
Related Companies and Tools
This page (TSE:CWEB) was last updated on 3/16/2025 by MarketBeat.com Staff
